PACT Brief Overview
description
Transcript of PACT Brief Overview
© 2013 Autism Speaks Inc. Autism Speaks and Autism Speaks It’s Time To Listen & Design are registered trademarks owned by Autism Speaks Inc. All rights reserved.
Preclinical Au,sm Consor,um for Therapeu,cs (PACT) Your partner to enable discovery of new medica6ons for ASD
Jacqueline
Crawley, Ph.D.
Carrie Jones, Ph.D.
Mustafa Sahin, M.D., Ph.D.
Daniel Smith, Ph.D.
To partner with PACT, contact: Daniel.Smith@Au,smSpeaks.org
What: a preclinical target validation platform for novel ASD medicines
Why: to reduce risk & increase successful
investment in ASD drug discovery
© 2013 Autism Speaks Inc. Autism Speaks and Autism Speaks It’s Time To Listen & Design are registered trademarks owned by Autism Speaks Inc. All rights reserved.
PACT Advantages ü Built for industry partnerships (Contact: Daniel.Smith@Au,smSpeaks.org)
ü Exper,se: PACT PIs and Advisors have strong experDse in: Au6sm medical and behavioral care, Au6sm therapeu6cs and drug discovery and development, Au6sm gene6cs and gene6c animal models, Neuropsychopharmacology.
ü CuFng-‐edge: PACT offers the latest geneDc rodent models of ASD, including mice and rats with mutaDons in risk genes for auDsm.
ü Reliable: The PACT plaGorm has been well-‐replicated in independent cohorts of each rodent model.
ü Transla,onal: EEG signatures, seizure analysis, social and repeDDve behaviors, circadian rhythms, cogniDve, sensory, anxiety-‐related, and other assays relevant to the diagnosDc and associated symptoms of auDsm.